Prognose
Analytikernes gennemsnitlige kursmål er 1,82 € (-6,67 %). Medianen er 1,82 € (-6,67 %).
| Køb |
8 |
| Behold |
4 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Accuray reports mixed Q4 results: revenue weaker, stock under pressure
Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » Mere på de.investing.com
Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence
Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » Mere på de.investing.com
Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs
Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » Mere på de.investing.com
Accuray reports 12% revenue decline in Q2 FY26 and lowers full-year guidance
Accuray reported Q2 FY26 revenue of $102.2 million (-12%), with product revenue down 26% to $45.0 million and service revenue up 4% to $57.2 million. Gross margin fell to 23.5% and adjusted EBITDA declined to -$1.9 million. Shipments through the China joint venture dropped sharply (11 vs. 27 units), weighing on reporting and margins. The company cut its full-year guidance to $440–450 million in revenue and $22–25 million in adjusted EBITDA, and plans $13 million in restructuring charges and a 15% workforce reduction. » Mere på de.investing.com
Accuray: board member Byron C. Scott to resign effective December 31, 2025
Byron C. Scott has announced his resignation from Accuray’s board of directors, effective December 31, 2025. In a filing with the SEC, the company said the resignation is not due to any disagreements with Accuray or its boards. No other changes to the board or management were disclosed. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2022 har Accuray allerede udloddet 0,62 € i udbytte. Den seneste udlodning fandt sted i juni 2022.
Virksomhedstal
I det seneste kvartal havde Accuray en omsætning på 76,39 mio. € og et nettoresultat på 8,95 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 76,39 mio. | 4,58 % |
| Bruttofortjeneste | 23,03 mio. | 1,79 % |
| Nettoresultat | 8,95 mio. | 148,43 % |
| EBITDA | 19,85 mio. | 302,89 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 6,83 mio. € |
Antal aktier | 3 mio. |
Højeste/laveste i 52 uger | 41,19 € - 2,17 € |
| Udbytte | Nej |
Beta | 1,38 |
P/E (PE Ratio) | -0,43 |
PEG (PEG Ratio) | 0,01 |
K/I (PB Ratio) | 0,16 |
P/S (PS Ratio) | 0,02 |
Virksomhedsprofil
Accuray Incorporated designer, udvikler, fremstiller og sælger strålekirurgi- og strålebehandlingssystemer til behandling af tumorer i Amerika, Europa, Mellemøsten, Indien, Afrika, Japan, Kina og resten af Asien-Stillehavsregionen. Selskabet tilbyder CyberKnife-systemet, et robotbaseret system til stereotaktisk strålekirurgi og stereotaktisk kropsstrålebehandling, der anvendes til behandling af forskellige typer kræft og tumorer i kroppen, såsom prostata, lunger, hjerne, rygsøjle, lever, bugspytkirtel og nyre. Selskabet leverer desuden TomoTherapy-systemet, herunder Radixact-systemet, som er et integreret strålebehandlingssystem designet til behandling af en række kræftformer. Derudover tilbyder selskabet kundesupport efter kontrakt, installation, uddannelse og andre professionelle serviceydelser. Selskabet markedsfører sine produkter primært direkte til kunder, herunder hospitaler og selvstændige behandlingsfaciliteter gennem sin salgsorganisation, samt til kunder gennem salgsagenter og indkøbsorganisationer i USA; og til kunder direkte og gennem distributører og salgsagenter internationalt. Accuray Incorporated blev stiftet i 1990 og har hovedkontor i Sunnyvale, Californien.
| Navn | Accuray |
| CEO | Stephen R. LaNeve |
| Hjemsted | Madison,
wi USA |
| Websted | |
| Sektor | Cykliske forbrugsvarer |
| Branche | Forbrugsgoder |
| Børsnotering | 08.02.2007 |
| Medarbejdere | 809 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ARAY |
London Stock Exchange | 0H8I.L |
Frankfurt | XEJ.F |
Düsseldorf | XEJ.DU |
London | 0H8I.L |
SIX | XEJ.SW |
München | XEJ.MU |